Sinotau aims to become Hong Kong’s ‘first nuclear-medicine stock’
The company is China’s first to obtain approval for its innovative radiopharmaceuticals Key Takeaways: Sinotau has filed to list in Hong Kong, offering up two commercialized products and a net…
ProfoundBio discovers the joys of having a wealthy owner
The company has become the latest in a recent string of China-related innovative drug makers to be purchased by larger foreign buyers Key Takeaways: Cancer treatment maker ProfoundBio announced it…
GenScript losses shrink on strong growth for cancer cell therapy
The pharma company’s losses narrowed 58% last year, as its life sciences and cell therapy businesses experienced strong growth Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year…
Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
Shares of the drug maker that licenses its products from other companies lost more than half their value in the two weeks after their listing Key Takeaways: Newly listed Adlai…
FAST NEWS: Beigene stock falls after Novartis terminates partnership
The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab. Looking up: Novartis will provide…
Sales success comes with side effects for drug maker BeiGene
The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…
Laekna IPO hopes to hitch a ride on Novartis ties
The producer of drugs licensed from third parties is banking on ties to the Swiss drug maker, as one of its key products nears the regulatory finish line Key Takeaways:…
Recent Articles
RELATED ARTICLES
-
Estenova aims to become a big name in medical aesthetics
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
- Neautus looks outward to boost its traditional medicine story
-
BRIEF: CATL targets $4 billion in Hong Kong IPO, poised to become year’s top listing
300750.SHE
